Improving predictability and transparency in DEA and FDA regulation : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, April 7, 2014
(Visualizza in formato marc)
(Visualizza in BIBFRAME)
| Titolo: |
Improving predictability and transparency in DEA and FDA regulation : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, April 7, 2014
|
| Pubblicazione: | Washington : , : U.S. Government Publishing Office, , 2015 |
| Descrizione fisica: | 1 online resource (iv, 217 pages) |
| Soggetto topico: | Drugs of abuse - Law and legislation - United States |
| Drugs - Law and legislation - United States | |
| Drug approval - United States | |
| Drug accessibility - United States | |
| Soggetto genere / forma: | Legislative hearings. |
| Note generali: | Title from title screen (viewed on July 24, 2015). |
| Paper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office. | |
| "Serial No. 113-147." | |
| Nota di bibliografia: | Includes bibliographical references. |
| Altri titoli varianti: | Improving predictability and transparency in DEA and FDA regulation |
| Titolo autorizzato: | Improving predictability and transparency in DEA and FDA regulation |
| Formato: | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione: | Inglese |
| Record Nr.: | 9910703844903321 |
| Lo trovi qui: | Univ. Federico II |
| Opac: | Controlla la disponibilità qui |